JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
$218.42
arrow_downward
-1.81%(-4.03) 1 日
$218.42
0.00% (0.00)
bedtime時間外取引
終了: 10月9日, 16:00:01 GMT-4 · USD
search
すべての記号
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_autoJAZZ の上位の分析情報を生成しています...
始値
$221.79
高値
$227.00
安値
$213.20
時価総額
141.79億
平均出来高
93.55万
取引量
128.85万
株価収益率
14.93
52 週高値
$266.38
52 週安値
$128.80
EPS
$14.63
ベータ版
0.37
発行済株式数
6491.50万
従業員数
2890
始値
$221.79
高値
$227.00
安値
$213.20
時価総額
141.79億
平均出来高
93.55万
取引量
128.85万
株価収益率
14.93
52 週高値
$266.38
52 週安値
$128.80
EPS
$14.63
ベータ版
0.37
発行済株式数
6491.50万
従業員数
2890
ニュース記事
情報源: ウェブソース、ニュース パートナー
Investing.com Nigeria
·
9 時間前
Form 144 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY For: 10 October
Traders Union
·
1 日前
Jazz Pharmaceuticals gets Cramer backing in CNBC stock call segment
プロフィール
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Jazz Pharmaceuticals PLC について